| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 28 | 2024 | 2989 | 2.290 |
Why?
|
| Mutation | 33 | 2024 | 6343 | 2.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2025 | 222 | 1.700 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2025 | 216 | 1.650 |
Why?
|
| Brain Neoplasms | 14 | 2023 | 1406 | 1.280 |
Why?
|
| Genomics | 19 | 2024 | 1677 | 1.260 |
Why?
|
| Histiocytosis, Langerhans-Cell | 6 | 2025 | 240 | 1.240 |
Why?
|
| Precision Medicine | 7 | 2024 | 361 | 1.170 |
Why?
|
| Xanthogranuloma, Juvenile | 3 | 2017 | 34 | 1.090 |
Why?
|
| Glioma | 7 | 2025 | 535 | 1.050 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2024 | 453 | 1.050 |
Why?
|
| Medical Oncology | 5 | 2024 | 245 | 0.990 |
Why?
|
| Pyrimidines | 4 | 2025 | 420 | 0.970 |
Why?
|
| Child | 52 | 2025 | 25843 | 0.960 |
Why?
|
| Circulating Tumor DNA | 2 | 2023 | 39 | 0.950 |
Why?
|
| Biomarkers, Tumor | 6 | 2023 | 1692 | 0.940 |
Why?
|
| Medulloblastoma | 5 | 2020 | 571 | 0.920 |
Why?
|
| DNA, Neoplasm | 4 | 2020 | 301 | 0.870 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2023 | 964 | 0.860 |
Why?
|
| Glioblastoma | 6 | 2015 | 372 | 0.820 |
Why?
|
| Molecular Targeted Therapy | 8 | 2022 | 407 | 0.810 |
Why?
|
| Germ-Line Mutation | 11 | 2025 | 368 | 0.790 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 502 | 0.750 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 128 | 0.740 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 460 | 0.730 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2009 | 82 | 0.720 |
Why?
|
| Young Adult | 21 | 2025 | 9917 | 0.720 |
Why?
|
| MyoD Protein | 1 | 2021 | 26 | 0.720 |
Why?
|
| DNA Copy Number Variations | 5 | 2022 | 1036 | 0.720 |
Why?
|
| Colorectal Neoplasms | 13 | 2022 | 639 | 0.710 |
Why?
|
| Benzimidazoles | 1 | 2022 | 136 | 0.700 |
Why?
|
| DNA Mutational Analysis | 9 | 2019 | 841 | 0.700 |
Why?
|
| Child, Preschool | 24 | 2025 | 14859 | 0.690 |
Why?
|
| Humans | 109 | 2025 | 133269 | 0.690 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 424 | 0.650 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 96 | 0.640 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 1013 | 0.640 |
Why?
|
| Sequence Analysis, DNA | 12 | 2022 | 1830 | 0.640 |
Why?
|
| Adolescent | 27 | 2025 | 20547 | 0.620 |
Why?
|
| Infant | 19 | 2025 | 13230 | 0.590 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 211 | 0.580 |
Why?
|
| Cerebellar Neoplasms | 5 | 2020 | 461 | 0.570 |
Why?
|
| Erdheim-Chester Disease | 2 | 2015 | 28 | 0.560 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2015 | 45 | 0.560 |
Why?
|
| MAP Kinase Signaling System | 5 | 2024 | 323 | 0.560 |
Why?
|
| Histiocytes | 1 | 2017 | 25 | 0.550 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 259 | 0.540 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2025 | 236 | 0.540 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 115 | 0.530 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 259 | 0.500 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2024 | 33 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2024 | 3363 | 0.490 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 21 | 0.480 |
Why?
|
| Ependymoma | 3 | 2022 | 176 | 0.480 |
Why?
|
| Genes, Neoplasm | 4 | 2010 | 90 | 0.480 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 115 | 0.470 |
Why?
|
| Lymph Nodes | 1 | 2017 | 395 | 0.470 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 111 | 0.460 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 624 | 0.460 |
Why?
|
| Vincristine | 1 | 2015 | 196 | 0.450 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 1849 | 0.450 |
Why?
|
| Nerve Tissue Proteins | 8 | 2017 | 1152 | 0.450 |
Why?
|
| Exome | 7 | 2024 | 1086 | 0.440 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 251 | 0.440 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 138 | 0.440 |
Why?
|
| Male | 43 | 2025 | 65527 | 0.430 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2025 | 625 | 0.430 |
Why?
|
| Repressor Proteins | 2 | 2015 | 872 | 0.420 |
Why?
|
| Incidental Findings | 1 | 2014 | 128 | 0.410 |
Why?
|
| Genetics, Medical | 1 | 2014 | 123 | 0.410 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2010 | 216 | 0.410 |
Why?
|
| Female | 43 | 2025 | 71454 | 0.400 |
Why?
|
| DNA Methylation | 3 | 2022 | 1140 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2017 | 2855 | 0.390 |
Why?
|
| Genetic Counseling | 3 | 2018 | 246 | 0.380 |
Why?
|
| Genome, Human | 8 | 2018 | 1340 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2024 | 211 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 2125 | 0.370 |
Why?
|
| Adult | 27 | 2025 | 31648 | 0.360 |
Why?
|
| Pyrazoles | 3 | 2025 | 334 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 348 | 0.350 |
Why?
|
| Oncologists | 2 | 2023 | 31 | 0.340 |
Why?
|
| Transcription Factors | 5 | 2025 | 2720 | 0.340 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1558 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1310 | 0.330 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2877 | 0.330 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2022 | 75 | 0.320 |
Why?
|
| Oncogenes | 1 | 2010 | 181 | 0.320 |
Why?
|
| Sarcoma | 3 | 2018 | 209 | 0.320 |
Why?
|
| Astrocytoma | 2 | 2009 | 111 | 0.320 |
Why?
|
| Parents | 3 | 2024 | 1073 | 0.310 |
Why?
|
| Neurodegenerative Diseases | 2 | 2025 | 284 | 0.300 |
Why?
|
| Nanoparticles | 3 | 2016 | 289 | 0.300 |
Why?
|
| Biomedical Research | 4 | 2021 | 551 | 0.300 |
Why?
|
| Gene Dosage | 6 | 2018 | 456 | 0.300 |
Why?
|
| Signal Transduction | 9 | 2024 | 4918 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 612 | 0.290 |
Why?
|
| DNA-Binding Proteins | 8 | 2024 | 2145 | 0.290 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 818 | 0.290 |
Why?
|
| Disclosure | 3 | 2019 | 154 | 0.280 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 2 | 1998 | 23 | 0.270 |
Why?
|
| Drug Therapy | 2 | 2018 | 93 | 0.270 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 712 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1340 | 0.270 |
Why?
|
| Gangliosides | 2 | 2025 | 73 | 0.260 |
Why?
|
| Muscular Atrophy, Spinal | 4 | 2000 | 47 | 0.260 |
Why?
|
| Frameshift Mutation | 4 | 2011 | 201 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2025 | 356 | 0.240 |
Why?
|
| Pediatrics | 3 | 2021 | 1220 | 0.240 |
Why?
|
| Exons | 8 | 2009 | 825 | 0.240 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 1408 | 0.240 |
Why?
|
| Decision Making | 4 | 2024 | 701 | 0.240 |
Why?
|
| Receptor, trkA | 1 | 2025 | 18 | 0.230 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2025 | 23 | 0.230 |
Why?
|
| Research Subjects | 2 | 2015 | 55 | 0.230 |
Why?
|
| Gene Fusion | 1 | 2025 | 61 | 0.220 |
Why?
|
| Phthalazines | 1 | 2024 | 15 | 0.220 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 43 | 0.220 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2024 | 64 | 0.220 |
Why?
|
| Interleukin-15 | 1 | 2025 | 96 | 0.220 |
Why?
|
| United States | 8 | 2024 | 11723 | 0.220 |
Why?
|
| Aminopyridines | 1 | 2024 | 60 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 56 | 0.210 |
Why?
|
| Prognosis | 5 | 2025 | 5042 | 0.200 |
Why?
|
| Clinical Protocols | 2 | 2022 | 245 | 0.200 |
Why?
|
| Meningioma | 1 | 2025 | 141 | 0.200 |
Why?
|
| Pyrroles | 1 | 2024 | 185 | 0.200 |
Why?
|
| Genetic Testing | 5 | 2024 | 1101 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 4 | 2009 | 739 | 0.190 |
Why?
|
| Mutation, Missense | 6 | 2014 | 946 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2025 | 216 | 0.190 |
Why?
|
| Piperazines | 1 | 2024 | 256 | 0.190 |
Why?
|
| Symporters | 1 | 2022 | 78 | 0.190 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 1915 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 5 | 2006 | 1582 | 0.190 |
Why?
|
| Hepatoblastoma | 2 | 2016 | 183 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 18 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 65 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 93 | 0.180 |
Why?
|
| Web Browser | 1 | 2021 | 8 | 0.180 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 254 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 511 | 0.180 |
Why?
|
| Multilingualism | 2 | 2018 | 43 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 103 | 0.180 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 57 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 899 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 177 | 0.170 |
Why?
|
| DNA Repair | 1 | 2024 | 573 | 0.170 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 40 | 0.170 |
Why?
|
| Trans-Activators | 1 | 2025 | 835 | 0.170 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 150 | 0.170 |
Why?
|
| Craniopharyngioma | 1 | 2020 | 35 | 0.170 |
Why?
|
| Professional-Family Relations | 2 | 2018 | 96 | 0.170 |
Why?
|
| Quinolines | 1 | 2021 | 115 | 0.170 |
Why?
|
| Clonal Evolution | 1 | 2020 | 49 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2023 | 822 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2021 | 1253 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 61 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 75 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 19 | 0.160 |
Why?
|
| Imidazoles | 1 | 2021 | 217 | 0.160 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 49 | 0.160 |
Why?
|
| Myofibromatosis | 1 | 2019 | 10 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 21 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.160 |
Why?
|
| Gene Amplification | 3 | 2008 | 245 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2025 | 550 | 0.160 |
Why?
|
| Organophosphates | 2 | 2016 | 21 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1325 | 0.160 |
Why?
|
| Airway Obstruction | 1 | 2021 | 168 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 449 | 0.150 |
Why?
|
| Phenotype | 6 | 2019 | 4577 | 0.150 |
Why?
|
| Interferon-alpha | 1 | 2020 | 246 | 0.150 |
Why?
|
| Founder Effect | 1 | 1998 | 34 | 0.150 |
Why?
|
| Military Personnel | 1 | 2021 | 204 | 0.150 |
Why?
|
| Breast Neoplasms | 6 | 2009 | 2762 | 0.150 |
Why?
|
| Software | 2 | 2021 | 732 | 0.150 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 200 | 0.150 |
Why?
|
| Empathy | 1 | 2018 | 64 | 0.140 |
Why?
|
| Quinazolines | 2 | 2016 | 185 | 0.140 |
Why?
|
| Genome | 1 | 2021 | 528 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 75 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 51 | 0.140 |
Why?
|
| Cultural Competency | 1 | 2018 | 53 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 1067 | 0.140 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 1341 | 0.140 |
Why?
|
| SMN Complex Proteins | 6 | 2000 | 6 | 0.140 |
Why?
|
| Communication | 2 | 2018 | 542 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 467 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2017 | 56 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2018 | 147 | 0.130 |
Why?
|
| Leukemia | 1 | 2020 | 374 | 0.130 |
Why?
|
| Enzyme Activation | 2 | 2016 | 640 | 0.130 |
Why?
|
| Language | 1 | 2018 | 223 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 6 | 2000 | 111 | 0.130 |
Why?
|
| Data Curation | 1 | 2016 | 14 | 0.130 |
Why?
|
| Technology, Pharmaceutical | 1 | 2016 | 21 | 0.130 |
Why?
|
| Genes, p53 | 2 | 2015 | 226 | 0.130 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2017 | 35 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 307 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2017 | 104 | 0.130 |
Why?
|
| Everolimus | 1 | 2016 | 51 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 123 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 1156 | 0.130 |
Why?
|
| Acetanilides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Aurora Kinases | 1 | 2016 | 27 | 0.120 |
Why?
|
| Language Development Disorders | 1 | 2017 | 179 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 226 | 0.120 |
Why?
|
| Haploinsufficiency | 1 | 2017 | 274 | 0.120 |
Why?
|
| Tandem Repeat Sequences | 1 | 2015 | 37 | 0.120 |
Why?
|
| Prodrugs | 1 | 2016 | 64 | 0.120 |
Why?
|
| Polymers | 1 | 2016 | 118 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 91 | 0.120 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 253 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 251 | 0.120 |
Why?
|
| Drug Design | 1 | 2016 | 168 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2015 | 316 | 0.120 |
Why?
|
| Receptor, trkB | 3 | 2025 | 25 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 116 | 0.120 |
Why?
|
| Parenting | 1 | 2019 | 349 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 795 | 0.120 |
Why?
|
| Cyclin B | 1 | 2014 | 23 | 0.110 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 26 | 0.110 |
Why?
|
| Sirolimus | 1 | 2016 | 239 | 0.110 |
Why?
|
| Exsanguination | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3131 | 0.110 |
Why?
|
| Telomere-Binding Proteins | 1 | 2014 | 45 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 232 | 0.110 |
Why?
|
| Microcephaly | 1 | 2017 | 354 | 0.110 |
Why?
|
| Genetic Research | 1 | 2015 | 56 | 0.110 |
Why?
|
| Animals | 12 | 2021 | 36215 | 0.110 |
Why?
|
| Histiocytosis, Sinus | 1 | 2014 | 34 | 0.110 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 34 | 0.110 |
Why?
|
| Survival Rate | 2 | 2010 | 2207 | 0.110 |
Why?
|
| Death | 1 | 2015 | 80 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 156 | 0.110 |
Why?
|
| Gene Duplication | 1 | 2015 | 372 | 0.110 |
Why?
|
| Mice | 7 | 2021 | 18935 | 0.100 |
Why?
|
| Point Mutation | 3 | 2010 | 358 | 0.100 |
Why?
|
| Consensus | 2 | 2019 | 724 | 0.100 |
Why?
|
| Informed Consent | 1 | 2015 | 345 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 1051 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 1001 | 0.100 |
Why?
|
| Ethics, Medical | 1 | 2015 | 401 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8628 | 0.100 |
Why?
|
| RNA-Binding Proteins | 6 | 2000 | 622 | 0.100 |
Why?
|
| Age Factors | 2 | 2016 | 2952 | 0.100 |
Why?
|
| Quality of Life | 1 | 2022 | 2165 | 0.100 |
Why?
|
| Middle Aged | 11 | 2025 | 28952 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 734 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3417 | 0.090 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2011 | 25 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1730 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2014 | 824 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 1013 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 982 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2014 | 449 | 0.090 |
Why?
|
| Tourniquets | 1 | 2011 | 12 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 53 | 0.090 |
Why?
|
| Algorithms | 5 | 2022 | 1731 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2018 | 2026 | 0.090 |
Why?
|
| Germ Cells | 2 | 2024 | 203 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5439 | 0.090 |
Why?
|
| Genotype | 3 | 2015 | 2720 | 0.090 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2011 | 128 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 1137 | 0.080 |
Why?
|
| Extremities | 1 | 2011 | 87 | 0.080 |
Why?
|
| Methylation | 1 | 2010 | 232 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2288 | 0.080 |
Why?
|
| Sodium Channels | 1 | 2011 | 109 | 0.080 |
Why?
|
| Disease Progression | 2 | 2014 | 2246 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1838 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1597 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 176 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 307 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 3664 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 498 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2007 | 787 | 0.080 |
Why?
|
| Smad4 Protein | 1 | 2009 | 59 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 3794 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2025 | 17554 | 0.070 |
Why?
|
| Translating | 2 | 2018 | 31 | 0.070 |
Why?
|
| HLA-A Antigens | 1 | 2008 | 34 | 0.070 |
Why?
|
| Chromatin | 1 | 2011 | 617 | 0.070 |
Why?
|
| National Human Genome Research Institute (U.S.) | 2 | 2018 | 19 | 0.070 |
Why?
|
| Family | 2 | 2024 | 593 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1611 | 0.070 |
Why?
|
| Histones | 1 | 2010 | 572 | 0.070 |
Why?
|
| Consensus Sequence | 1 | 2006 | 59 | 0.060 |
Why?
|
| Aged | 8 | 2025 | 21479 | 0.060 |
Why?
|
| Homozygote | 1 | 2008 | 562 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 3960 | 0.060 |
Why?
|
| Sequence Deletion | 3 | 2009 | 541 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 415 | 0.060 |
Why?
|
| Rats, Nude | 2 | 2016 | 11 | 0.060 |
Why?
|
| Patients | 2 | 2018 | 127 | 0.060 |
Why?
|
| Survival of Motor Neuron 2 Protein | 4 | 2000 | 13 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 496 | 0.060 |
Why?
|
| Survival of Motor Neuron 1 Protein | 4 | 2000 | 20 | 0.060 |
Why?
|
| Recurrence | 2 | 2022 | 1469 | 0.060 |
Why?
|
| Biopsy | 2 | 2020 | 1202 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2009 | 806 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 902 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 68 | 0.060 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 448 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 50 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 36 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2017 | 124 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2016 | 333 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 79 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 362 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 82 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 102 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2004 | 61 | 0.050 |
Why?
|
| Computational Biology | 5 | 2008 | 887 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 157 | 0.050 |
Why?
|
| Natural Killer T-Cells | 1 | 2025 | 84 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 944 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 48 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 69 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2010 | 945 | 0.050 |
Why?
|
| Benzamides | 1 | 2023 | 126 | 0.050 |
Why?
|
| Alleles | 2 | 1998 | 1697 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3983 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Teratoma | 1 | 2023 | 130 | 0.050 |
Why?
|
| Oligodendroglioma | 2 | 2014 | 24 | 0.050 |
Why?
|
| Centromere | 2 | 2000 | 75 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 245 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 234 | 0.050 |
Why?
|
| Nucleic Acid Heteroduplexes | 2 | 1998 | 17 | 0.050 |
Why?
|
| DNA Damage | 1 | 2024 | 517 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2025 | 13099 | 0.040 |
Why?
|
| Pedigree | 3 | 2014 | 1729 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 436 | 0.040 |
Why?
|
| Physicians | 2 | 2018 | 640 | 0.040 |
Why?
|
| Training Support | 1 | 2020 | 19 | 0.040 |
Why?
|
| Databases, Genetic | 2 | 2016 | 505 | 0.040 |
Why?
|
| Financing, Government | 1 | 2020 | 30 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 239 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 64 | 0.040 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 85 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 137 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4758 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cell Line | 2 | 2019 | 2853 | 0.040 |
Why?
|
| Equipment Design | 1 | 2021 | 604 | 0.040 |
Why?
|
| Pediatricians | 1 | 2020 | 71 | 0.040 |
Why?
|
| Heteroduplex Analysis | 1 | 1998 | 4 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2019 | 83 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 431 | 0.040 |
Why?
|
| Linguistics | 1 | 2018 | 20 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 150 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 330 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 42 | 0.040 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 163 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Transcriptome | 2 | 2018 | 1135 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 164 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 658 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1998 | 143 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 118 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 371 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 20 | 0.030 |
Why?
|
| Social Behavior | 1 | 2019 | 230 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 767 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 1997 | 72 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 60 | 0.030 |
Why?
|
| Telomere | 1 | 1998 | 227 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1433 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 52 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2559 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 50 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 71 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 67 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 254 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1999 | 378 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2017 | 102 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1997 | 111 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 56 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 326 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 148 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 157 | 0.030 |
Why?
|
| Population Groups | 1 | 2016 | 31 | 0.030 |
Why?
|
| Deoxycholic Acid | 1 | 2016 | 13 | 0.030 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Heterozygote | 1 | 1998 | 731 | 0.030 |
Why?
|
| Cholic Acid | 1 | 2016 | 20 | 0.030 |
Why?
|
| Naphthols | 1 | 2016 | 8 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2016 | 36 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 65 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 768 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 561 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 201 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 260 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1998 | 814 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 399 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2015 | 65 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 890 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 591 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 256 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2015 | 107 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2017 | 396 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 213 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1514 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 398 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 196 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 753 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 151 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 422 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 298 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 2785 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 614 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 367 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1307 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 780 | 0.030 |
Why?
|
| Military Medicine | 1 | 2014 | 51 | 0.030 |
Why?
|
| Bandages | 1 | 2014 | 59 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 558 | 0.030 |
Why?
|
| Manikins | 1 | 2014 | 138 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 757 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 683 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1965 | 0.020 |
Why?
|
| Patched Receptors | 1 | 2011 | 37 | 0.020 |
Why?
|
| Patched-1 Receptor | 1 | 2011 | 50 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2011 | 40 | 0.020 |
Why?
|
| Base Sequence | 2 | 2011 | 3153 | 0.020 |
Why?
|
| Ouabain | 1 | 2011 | 24 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1473 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2011 | 238 | 0.020 |
Why?
|
| Digoxin | 1 | 2011 | 43 | 0.020 |
Why?
|
| Pancreas | 1 | 2011 | 231 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 225 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2007 | 1118 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 395 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2011 | 268 | 0.020 |
Why?
|
| Breast | 1 | 2011 | 218 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 6582 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2011 | 165 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2011 | 166 | 0.020 |
Why?
|
| Stomach | 1 | 2011 | 236 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
| Codon, Terminator | 1 | 2009 | 27 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2011 | 400 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 101 | 0.020 |
Why?
|
| Colon | 1 | 2011 | 373 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 106 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 3416 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2008 | 27 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5199 | 0.020 |
Why?
|
| Motor Neurons | 2 | 2000 | 136 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 2050 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 1097 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1584 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2011 | 518 | 0.020 |
Why?
|
| Spinal Cord | 2 | 2000 | 275 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 196 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 169 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 670 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2006 | 74 | 0.020 |
Why?
|
| Epitopes | 1 | 2008 | 444 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 3224 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 415 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1364 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2008 | 1147 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 788 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 3 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2004 | 3 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2004 | 9 | 0.010 |
Why?
|
| MRE11 Homologue Protein | 1 | 2004 | 4 | 0.010 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2004 | 36 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1928 | 0.010 |
Why?
|
| Markov Chains | 1 | 2004 | 99 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 6544 | 0.010 |
Why?
|
| Fusion Proteins, gag-onc | 1 | 2003 | 1 | 0.010 |
Why?
|
| Receptor, EphA3 | 1 | 2003 | 1 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2004 | 144 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 180 | 0.010 |
Why?
|
| Receptor, trkC | 1 | 2003 | 4 | 0.010 |
Why?
|
| Guanylate Cyclase | 1 | 2003 | 38 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2092 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 63 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 765 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 1323 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 1095 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 1531 | 0.010 |
Why?
|
| Microinjections | 1 | 2000 | 51 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1706 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 269 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 702 | 0.010 |
Why?
|
| Brain Stem | 1 | 2000 | 119 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 960 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2004 | 844 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 7137 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2000 | 1136 | 0.010 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1997 | 47 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2000 | 1041 | 0.010 |
Why?
|
| DNA Primers | 1 | 1997 | 656 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 911 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 2523 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1757 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 1676 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1997 | 3719 | 0.000 |
Why?
|